Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 351.60K | 251.50K | -- | 247.10K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.60K | 251.50K | -- | 247.10K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 351.60K | 251.50K | -- | 247.10K | -- |
| SG&A Expenses | 459.20K | 591.90K | 743.90K | 1.19M | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.76M | 1.36M | 1.66M | 2.28M | 1.79M |
| Operating Income | -1.41M | -1.11M | -1.66M | -2.03M | -1.79M |
| Income Before Tax | -107.50K | -696.70K | -1.14M | -1.96M | -1.90M |
| Income Tax Expenses | 4.50K | 31.30K | 9.30K | 5.10K | 25.10K |
| Earnings from Continuing Operations | -112.00K | -728.10K | -1.15M | -1.97M | -1.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.00K | -728.10K | -1.15M | -1.97M | -1.93M |
| EBIT | -1.41M | -1.11M | -1.66M | -2.03M | -1.79M |
| EBITDA | -1.41M | -1.10M | -1.66M | -2.03M | -1.78M |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.13M | 121.27M |
| Average Diluted Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.13M | 121.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
